Black Diamond Therapeutics
Cambridge · Founded 2017
About Black Diamond Therapeutics
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small-molecule. It is engaged in discovering and developing small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, Mutation-Allostery-Pharmacology, which targets cancer mutations. Black Diamond focuses on the discovery and development of precision medicines for cancer that are directed against a novel class of allosteric mutant oncogenes. It also targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. It is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.
Company Facts
- Founded: 2017
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $272.1M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jun 2023)
- Ticker: nasdaq:BDTX
- Website: blackdiamondtherapeutics.com
- Phone: 617-417-5868
Industries & Categories
Biotechnology, Life Science, Medical
Social Profiles
Canonical: https://fsome.com/organization/black-diamond-therapeutics-125370 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.